231 related articles for article (PubMed ID: 24731186)
1. CD34(+) cell therapy is safe and effective in slowing the decline of hepatic reserve function in patients with decompensated liver cirrhosis.
Nakamura T; Torimura T; Iwamoto H; Kurogi J; Inoue H; Hori Y; Sumie S; Fukushima N; Sakata M; Koga H; Abe M; Ikezono Y; Hashimoto O; Ueno T; Oho K; Okamura T; Okuda S; Kawamoto A; Ii M; Asahara T; Sata M
J Gastroenterol Hepatol; 2014 Oct; 29(10):1830-8. PubMed ID: 24731186
[TBL] [Abstract][Full Text] [Related]
2. Autologous mobilized peripheral blood CD34(+) cell infusion in non-viral decompensated liver cirrhosis.
Sharma M; Rao PN; Sasikala M; Kuncharam MR; Reddy C; Gokak V; Raju B; Singh JR; Nag P; Nageshwar Reddy D
World J Gastroenterol; 2015 Jun; 21(23):7264-71. PubMed ID: 26109814
[TBL] [Abstract][Full Text] [Related]
3. Stem cell mobilization and collection in patients with liver cirrhosis.
Lorenzini S; Isidori A; Catani L; Gramenzi A; Talarico S; Bonifazi F; Giudice V; Conte R; Baccarani M; Bernardi M; Forbes SJ; Lemoli RM; Andreone P
Aliment Pharmacol Ther; 2008 May; 27(10):932-9. PubMed ID: 18315586
[TBL] [Abstract][Full Text] [Related]
4. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
[TBL] [Abstract][Full Text] [Related]
5. Combination of granulocyte colony-stimulating factor and erythropoietin improves outcomes of patients with decompensated cirrhosis.
Kedarisetty CK; Anand L; Bhardwaj A; Bhadoria AS; Kumar G; Vyas AK; David P; Trehanpati N; Rastogi A; Bihari C; Maiwall R; Garg HK; Vashishtha C; Kumar M; Bhatia V; Sarin SK
Gastroenterology; 2015 Jun; 148(7):1362-70.e7. PubMed ID: 25749502
[TBL] [Abstract][Full Text] [Related]
6. Peripheral blood stem cell mobilization by granulocyte colony-stimulating factor alone and engraftment kinetics following autologous transplantation in children and adolescents with solid tumor.
Watanabe H; Watanabe T; Suzuya H; Wakata Y; Kaneko M; Onishi T; Okamoto Y; Abe T; Kawano Y; Kagami S; Takaue Y
Bone Marrow Transplant; 2006 Apr; 37(7):661-8. PubMed ID: 16489358
[TBL] [Abstract][Full Text] [Related]
7. Autologous G-CSF-mobilized peripheral blood CD34+ cell therapy for diabetic patients with chronic nonhealing ulcer.
Tanaka R; Masuda H; Kato S; Imagawa K; Kanabuchi K; Nakashioya C; Yoshiba F; Fukui T; Ito R; Kobori M; Wada M; Asahara T; Miyasaka M
Cell Transplant; 2014 Feb; 23(2):167-79. PubMed ID: 23107450
[TBL] [Abstract][Full Text] [Related]
8. Peripheral blood progenitor cell mobilization with intermediate-dose cyclophosphamide, sequential granulocyte-macrophage-colony-stimulating factor and granulocyte-colony-stimulating factor, and scheduled commencement of leukapheresis in 225 patients undergoing autologous transplantation.
Bashey A; Donohue M; Liu L; Medina B; Corringham S; Ihasz A; Carrier E; Castro JE; Holman PR; Xu R; Law P; Ball ED; Lane TA
Transfusion; 2007 Nov; 47(11):2153-60. PubMed ID: 17958545
[TBL] [Abstract][Full Text] [Related]
9. CD34+ cells mobilized by cyclophosphamide and granulocyte colony-stimulating factor (G-CSF) are functionally different from CD34+ cells mobilized by G-CSF.
Cesana C; Carlo-Stella C; Regazzi E; Garau D; Sammarelli G; Caramatti C; Tabilio A; Mangoni L; Rizzoli V
Bone Marrow Transplant; 1998 Mar; 21(6):561-8. PubMed ID: 9543059
[TBL] [Abstract][Full Text] [Related]
10. [The follow-up of the mobilization of circulating hematopoietic progenitor cells by granulocyte growth factor (G-CSF) using flow cytometry].
De Arriba F; Ortuño F; Rivera J; Heras I; Funes C; Moraleda JM; Vicente V
Med Clin (Barc); 1995 Jan; 104(2):41-4. PubMed ID: 7532770
[TBL] [Abstract][Full Text] [Related]
11. GM-CSF-based mobilization effect in normal healthy donors for allogeneic peripheral blood stem cell transplantation.
Sohn SK; Kim JG; Seo KW; Chae YS; Jung JT; Suh JS; Lee KB
Bone Marrow Transplant; 2002 Jul; 30(2):81-6. PubMed ID: 12132046
[TBL] [Abstract][Full Text] [Related]
12. Beyond CD34+ cell dose: impact of method of peripheral blood hematopoietic stem cell mobilization (granulocyte-colony-stimulating factor [G-CSF], G-CSF plus plerixafor, or cyclophosphamide G-CSF/granulocyte-macrophage [GM]-CSF) on number of colony-forming unit-GM, engraftment, and Day +100 hematopoietic graft function.
Alexander ET; Towery JA; Miller AN; Kramer C; Hogan KR; Squires JE; Stuart RK; Costa LJ
Transfusion; 2011 Sep; 51(9):1995-2000. PubMed ID: 21392017
[TBL] [Abstract][Full Text] [Related]
13. Mobilization of peripheral blood stem cells following myelosuppressive chemotherapy: a randomized comparison of filgrastim, sargramostim, or sequential sargramostim and filgrastim.
Weaver CH; Schulman KA; Buckner CD
Bone Marrow Transplant; 2001 May; 27 Suppl 2():S23-9. PubMed ID: 11436117
[TBL] [Abstract][Full Text] [Related]
14. [Autologous peripheral blood stem cells mobilization with etoposide plus rhG-CSF versus cyclophosphamide plus rhG-CSF].
Shi YK; He XH; Han XH; Liu P; Yang JL; Zhou SY; Zhou AP; Zhang CG; Ai B
Ai Zheng; 2003 Dec; 22(12):1311-6. PubMed ID: 14693058
[TBL] [Abstract][Full Text] [Related]
15. Recombinant human granulocyte-colony-stimulating factor-mobilized and apheresis-collected endothelial progenitor cells: a novel blood cell component for therapeutic vasculogenesis.
Körbling M; Reuben JM; Gao H; Lee BN; Harris DM; Cogdell D; Giralt SA; Khouri IF; Saliba RM; Champlin RE; Zhang W; Estrov Z
Transfusion; 2006 Oct; 46(10):1795-802. PubMed ID: 17002637
[TBL] [Abstract][Full Text] [Related]
16. Biosimilar granulocyte-colony-stimulating factor for mobilization of autologous peripheral blood stem cells in pediatric hematology-oncology patients.
Cesaro S; Tridello G; Prete A; Dallorso S; Cannata E; Massaccesi E; Risso M; De Bortoli M; Caselli D
Transfusion; 2015 Feb; 55(2):246-52. PubMed ID: 25070657
[TBL] [Abstract][Full Text] [Related]
17. Controlled trials in hepatitis B virus-related decompensate liver cirrhosis: peripheral blood monocyte transplant versus granulocyte-colony-stimulating factor mobilization therapy.
Han Y; Yan L; Han G; Zhou X; Hong L; Yin Z; Zhang X; Wang S; Wang J; Sun A; Liu Z; Xie H; Wu K; Ding J; Fan D
Cytotherapy; 2008; 10(4):390-6. PubMed ID: 18574771
[TBL] [Abstract][Full Text] [Related]
18. [The effect of matrix metalloproteinase-9 in granulocyte colony stimulation factor-induced stem cell mobilization].
Jin FY; Qiu LG; Li QC; Meng HX; Wang YF; Yu Z; Li Q; Han JL
Zhonghua Yi Xue Za Zhi; 2006 Nov; 86(42):2966-70. PubMed ID: 17288807
[TBL] [Abstract][Full Text] [Related]
19. CD34+ dose-driven administration of granulocyte colony-stimulating factor after high-dose chemotherapy in lymphoma patients.
Todisco E; Castagna L; Sarina B; Mazza R; Magagnoli M; Balzarotti M; Nozza A; Siracusano L; Timofeeva I; Anastasia A; Demarco M; Santoro A
Eur J Haematol; 2007 Feb; 78(2):111-6. PubMed ID: 17313558
[TBL] [Abstract][Full Text] [Related]
20. Peripheral blood progenitor cell collection without close monitoring of peripheral blood CD34+ cells: A feasible strategy for multiple myeloma or pre-treated Non-Hodgkin's Lymphoma patients mobilized with low-dose cyclophosphamide plus G-CSF.
Callera F; Cavenaghi L; de Melo CM
Transfus Apher Sci; 2009 Apr; 40(2):91-5. PubMed ID: 19233728
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
